A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)Erica Brivio, C. Michel Zwaan, Cristina Díaz de Heredia et al.|Blood|2020Cited by 93
A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 StudyErica Brivio, C. Michel Zwaan, Marta López‐Yurda et al.|Blood|2019Cited by 8